Analyst Ratings for Krystal Biotech (KRYS)
KRYS Rating Summary
KRYS Price Target Summary
- Highest: $140.00 (Chardan Capital Markets)
- Lowest: $93.00 (Goldman Sachs)
- Average: $112.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$112.50 (+86.7%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
Avg. $ Target:
$112.50 (+86.7%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 1/18/2022 | BofA Securities | Alec Stranahan | New Coverage | Buy (N/A) |
110.00 (N/A) |
62.28 (60.26) |
-3.24% | Details |
| 7/20/2021 | Goldman Sachs » Updated 2/28/2022 |
Madhu Kumar | Upgrade | Buy (Neutral) |
93.00 (125.00) |
61.09 (60.26) |
-1.36% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
KRYS Ratings News
- Cowen Reiterates Outperform Rating on Krystal Biotech (KRYS), "Remain Encouraged by New Durability Analyses"
- Cowen Reiterates Krystal Biotech (KRYS) at Outperform, $111 PT, Encouraged by Impressive Skin Changes of KB301 Which "FDA Places Significant Weight On"
- Krystal Biotech (KRYS) PT Lowered to $107 at H. C. Wainwright, Buy Rating Maintained Ahead of Vyjuvek Launch
- See More
